Susan M. Flint
Keine laufenden Positionen mehr
Profil
Susan M.
Flint worked as a Director of Technology Transfer at Pressure BioSciences, Inc. from 1995 to 1997.
She then worked as an Executive Director and Head of Clinical Operations at Oxyrane UK Ltd.
and Oxyrane, Ltd.
respectively.
After that, she worked as a Vice President of Clinical Operations at Navidea Biopharmaceuticals, Inc. and as a Senior Vice President of Drug Development at Alseres Pharmaceuticals, Inc. She also worked as a VP of Regulatory Affairs and Clinical Operations at EPIX Pharmaceuticals, Inc. and as a Senior Vice President of Drug Development at Cato Research LLC.
From 2014 to 2019, she worked as a Vice President and Head of Clinical Operations at Wilson Therapeutics AB.
Ms. Flint received her undergraduate degree from Bridgewater State College and her graduate degree from Northeastern University.
Ehemalige bekannte Positionen von Susan M. Flint
| Unternehmen | Position | Ende |
|---|---|---|
| WILSON THERAPEUTICS AB | Geschäftsführer | 01.03.2019 |
| PRESSURE BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 |
| NAVIDEA BIOPHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Oxyrane, Ltd. | Technik-/Wissenschafts-/F&E-Leiter | - |
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Susan M. Flint
| Bridgewater State College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Health Technology |
| ALSERES PHARMACEUTICALS, INC. | Health Technology |
| PRESSURE BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Cato Research LLC
 Cato Research LLC Miscellaneous Commercial ServicesCommercial Services Cato Research LLC operates as an international regulatory and clinical contract research organization. It offers clinical strategy, clinical trial services, data management and biostatistics, medical and pharmacovigilance, medical writing, pharmacokinetics, preclinical/nonclinical services, project management, quality assurance, and regulatory affairs. The company was founded by Allen Cato and Lynda Sutton in 1988 and is headquartered in Durham, NC. | Commercial Services |
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
| Oxyrane, Ltd. |
